Study Investigating Acthar Gel in the Treatment of ALS Discontinued
Mallinckrodt has permanently discontinued the phase 2b PENNANT trial investigating Acthar Gel (repository corticotrophin) for the treatment of amyotrophic lateral sclerosis.
Amyotrophic Lateral Sclerosis
AAN: Professional Soccer Players Show Increased Risk for ALS
Professional soccer players may have an increased risk for amyotrophic lateral sclerosis.
Tiglutik Now Available for the Treatment of Amyotrophic Lateral Sclerosis
Tiglutik is supplied as a thickened riluzole liquid that is intended to ease administration for patients with dysphagia.
FDA Approves Tiglutik for the Treatment of Amyotrophic Lateral Sclerosis
The FDA approval was supported by data from bioavailability studies comparing riluzole tablets and Tiglutik oral suspension.
Rasagiline Plus Riluzole is Safe, May Improve Survival in ALS
Rasagiline was associated with a significant effect on survival within 6 months of treatment in an exploratory analysis.
Immunotherapy Promising for Slowing Progression of ALS
A new immunotherapy appears to be well tolerated and possibly of benefit in patients with amyotrophic lateral sclerosis.
Linear Link for Physical Activity, Amyotrophic Lateral Sclerosis
There is a linear correlation for physical activity with amyotrophic lateral sclerosis.
MAPT H1 Haplotype Implicated in ALS Risk, With Genetic Overlap Between ALS and FTD
Investigators sought to identify genetic factors that may contribute to the risk for neurodegenerative diseases, such as amyotrophic lateral sclerosis and frontotemporal dementia.
Sensory Cortex Hyperexcitability Predicts Shorter Survival in ALS
Investigators assessed patients with sporadic ALS to determine the relationship between somatosensory cortex excitability and survival prognosis.
Occupational Exposure to Diesel Exhaust Tied to ALS Risk
Researchers found that for men with any occupational exposure to diesel exhaust, the odds ratio for amyotrophic lateral sclerosis increased with increasing lag periods.
Next post in AAN 2018 Coverage
